|Assessment Status||Rapid Review Complete|
|Indication||As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥50% tumour cells (TC) or ≥10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.|
|Rapid review commissioned||29/03/2021|
|Rapid review completed||21/04/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that atezolizumab not be considered for reimbursement at the submitted price*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations October 2021.